GENERIC MFR. BOLAR IS ONLY STRONG PERFORMER AS ALL COMPONENTS DROP
GENERIC MFR. BOLAR IS ONLY STRONG PERFORMER AS ALL COMPONENTS DROP Generic mfr. Bolar (up 2-1/2 to 22-1/2) was the only issue on the "F-D-C" Index to post a strong gain as all components lost ground during the week ended March 9. After Bolar, the best weekly performances were turned in by Pennwalt (up 3/4 to 37-1/4), Upjohn (up 3/4 to 58-5/8), and Searle (up 5/8 to 47-1/4). Overall only eight stocks advanced, while 41 declined and four remained unchanged. Hospital supply stocks continued to perform poorly as American Hospital Supply fell 2-1/2 to 34-1/4, and Baxter slipped 7/8 to 17. On Wednesday Baxter hit a low 16-3/8. Abbott remained unchanged for the week at 40-3/8. Jack Eckerd (up 1/8 to 25-1/2) was the only chain to advance on the week. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth